(TMO) Thermo Fisher Scientific - Overview
Stock: Reagents, Instruments, Consumables, Diagnostics, Instruments
| Risk 5d forecast | |
|---|---|
| Volatility | 23.0% |
| Relative Tail Risk | -6.98% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.04 |
| Alpha | -16.69 |
| Character TTM | |
|---|---|
| Beta | 0.703 |
| Beta Downside | 0.968 |
| Drawdowns 3y | |
|---|---|
| Max DD | 37.28% |
| CAGR/Max DD | -0.04 |
EPS (Earnings per Share)
Revenue
Description: TMO Thermo Fisher Scientific February 28, 2026
Thermo Fisher Scientific (NYSE: TMO) operates four core segments: Life Sciences Solutions, delivering reagents, instruments and consumables for drug discovery, vaccine production and disease diagnostics; Analytical Instruments, supplying hardware, software and services to pharma, biotech, academia and industrial labs; Specialty Diagnostics, offering immunodiagnostic kits, microbiology media, transplant typing and related consumables; and Laboratory Products & Biopharma Services, which provides a broad portfolio of lab supplies and contract manufacturing through brands such as Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
In its most recent fiscal year (2023), Thermo Fisher generated $46.2 billion in revenue-a 10 % year-over-year increase-driven largely by strong demand for COVID-19 testing supplies and expanding biopharma outsourcing. Adjusted earnings per share rose to $9.10, and the company posted an operating margin of roughly 15 %, underscoring its ability to translate top-line growth into profitability.
Key sector catalysts include accelerating global biotech R&D spend (projected to exceed $600 billion by 2026), an aging population that fuels demand for clinical diagnostics, and sustained government investment in vaccine and therapeutic manufacturing capacity. Thermo Fisher’s 2021 acquisition of contract research organization PPD, together with its ongoing integration of specialty-diagnostic assets, positions it to capture a larger share of the growing outsourced-services market.
For a deeper quantitative look, you might explore Thermo Fisher’s valuation metrics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 6.71b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -1.76 > 1.0 |
| NWC/Revenue: 30.34% < 20% (prev 20.53%; Δ 9.80% < -1%) |
| CFO/TA 0.07 > 3% & CFO 7.82b > Net Income 6.71b |
| Net Debt (29.53b) to EBITDA (11.29b): 2.62 < 3 |
| Current Ratio: 1.89 > 1.5 & < 3 |
| Outstanding Shares: last quarter (377.0m) vs 12m ago -1.57% < -2% |
| Gross Margin: 39.46% > 18% (prev 0.41%; Δ 3905 % > 0.5%) |
| Asset Turnover: 42.91% > 50% (prev 44.06%; Δ -1.15% > 0%) |
| Interest Coverage Ratio: 6.00 > 6 (EBITDA TTM 11.29b / Interest Expense TTM 1.42b) |
Altman Z'' 3.99
| A: 0.12 (Total Current Assets 28.71b - Total Current Liabilities 15.19b) / Total Assets 110.34b |
| B: 0.51 (Retained Earnings 55.90b / Total Assets 110.34b) |
| C: 0.08 (EBIT TTM 8.51b / Avg Total Assets 103.83b) |
| D: 0.94 (Book Value of Equity 53.41b / Total Liabilities 56.93b) |
| Altman-Z'' Score: 3.99 = AA |
Beneish M -3.09
| DSRI: 0.89 (Receivables 8.90b/9.63b, Revenue 44.56b/42.88b) |
| GMI: 1.03 (GM 39.46% / 40.51%) |
| AQI: 0.97 (AQ_t 0.64 / AQ_t-1 0.66) |
| SGI: 1.04 (Revenue 44.56b / 42.88b) |
| TATA: -0.01 (NI 6.71b - CFO 7.82b) / TA 110.34b) |
| Beneish M-Score: -3.09 (Cap -4..+1) = AA |
What is the price of TMO shares?
Over the past week, the price has changed by +0.97%, over one month by -17.00%, over three months by -12.26% and over the past year by -2.12%.
Is TMO a buy, sell or hold?
- StrongBuy: 18
- Buy: 7
- Hold: 6
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the TMO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 666.5 | 28.1% |
| Analysts Target Price | 666.5 | 28.1% |
TMO Fundamental Data Overview February 21, 2026
P/E Forward = 20.284
P/S = 4.3436
P/B = 3.5508
P/EG = 1.8594
Revenue TTM = 44.56b USD
EBIT TTM = 8.51b USD
EBITDA TTM = 11.29b USD
Long Term Debt = 35.85b USD (from longTermDebt, last quarter)
Short Term Debt = 3.53b USD (from shortTermDebt, last quarter)
Debt = 39.38b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 29.53b USD (from netDebt column, last quarter)
Enterprise Value = 223.07b USD (193.53b + Debt 39.38b - CCE 9.85b)
Interest Coverage Ratio = 6.00 (Ebit TTM 8.51b / Interest Expense TTM 1.42b)
EV/FCF = 35.45x (Enterprise Value 223.07b / FCF TTM 6.29b)
FCF Yield = 2.82% (FCF TTM 6.29b / Enterprise Value 223.07b)
FCF Margin = 14.12% (FCF TTM 6.29b / Revenue TTM 44.56b)
Net Margin = 15.07% (Net Income TTM 6.71b / Revenue TTM 44.56b)
Gross Margin = 39.46% ((Revenue TTM 44.56b - Cost of Revenue TTM 26.98b) / Revenue TTM)
Gross Margin QoQ = 37.95% (prev 41.83%)
Tobins Q-Ratio = 2.02 (Enterprise Value 223.07b / Total Assets 110.34b)
Interest Expense / Debt = 0.93% (Interest Expense 365.0m / Debt 39.38b)
Taxrate = 7.21% (153.0m / 2.12b)
NOPAT = 7.90b (EBIT 8.51b * (1 - 7.21%))
Current Ratio = 1.89 (Total Current Assets 28.71b / Total Current Liabilities 15.19b)
Debt / Equity = 0.74 (Debt 39.38b / totalStockholderEquity, last quarter 53.41b)
Debt / EBITDA = 2.62 (Net Debt 29.53b / EBITDA 11.29b)
Debt / FCF = 4.69 (Net Debt 29.53b / FCF TTM 6.29b)
Total Stockholder Equity = 51.09b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.47% (Net Income 6.71b / Total Assets 110.34b)
RoE = 13.14% (Net Income TTM 6.71b / Total Stockholder Equity 51.09b)
RoCE = 9.79% (EBIT 8.51b / Capital Employed (Equity 51.09b + L.T.Debt 35.85b))
RoIC = 9.26% (NOPAT 7.90b / Invested Capital 85.34b)
WACC = 7.22% (E(193.53b)/V(232.92b) * Re(8.51%) + D(39.38b)/V(232.92b) * Rd(0.93%) * (1-Tc(0.07)))
Discount Rate = 8.51% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.43%
[DCF] Terminal Value 80.51% ; FCFF base≈6.68b ; Y1≈6.42b ; Y5≈6.26b
[DCF] Fair Price = 269.7 (EV 130.87b - Net Debt 29.53b = Equity 101.34b / Shares 375.7m; r=7.22% [WACC]; 5y FCF grow -5.31% → 2.90% )
EPS Correlation: 5.05 | EPS CAGR: -2.59% | SUE: 0.88 | # QB: 2
Revenue Correlation: 4.24 | Revenue CAGR: 0.88% | SUE: 3.38 | # QB: 4
EPS next Quarter (2026-03-31): EPS=5.29 | Chg7d=-0.287 | Chg30d=-0.294 | Revisions Net=-15 | Analysts=20
EPS current Year (2026-12-31): EPS=24.54 | Chg7d=+0.000 | Chg30d=-0.116 | Revisions Net=+0 | Growth EPS=+7.3% | Growth Revenue=+5.1%
EPS next Year (2027-12-31): EPS=26.94 | Chg7d=+0.002 | Chg30d=-0.311 | Revisions Net=-12 | Growth EPS=+9.8% | Growth Revenue=+5.3%
[Analyst] Revisions Ratio: -1.00 (0 Up / 15 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.1% (Discount Rate 8.5% - Earnings Yield 3.4%)
[Growth] Growth Spread = -0.1% (Analyst 5.0% - Implied 5.1%)